Ospedale San Gerardo - ASST Monza

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer2 trials
• Endometrial cancer1 trial
• Lung cancer1 trial

Phase

• Phase 33 trials
• Phase 11 trial

Status

• Active, not recruiting2 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company1 trial
• Karyopharm Therapeutics Inc1 trial
• OnKure, Inc.1 trial
• Stemline Therapeutics, Inc.1 trial

Running trials

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Diego Cortinovis (principal investigator)

• Active, not recruiting

  First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

  NCT06239467· Phase 1· OnKure, Inc.· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source